Search research articles
Contact Us
Filters
Showing results (11-20 of 48) with videos related to
Page
of 5
Sort By:
Current Drug Targets
|
July 23, 2011
Targeting aurora kinases in cancer treatment
Kevin R Kelly, Jeffrey Ecsedy, Devalingam Mahalingam, et al.
Blood Advances
|
April 25, 2019
Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity
Jennifer S Carew, Claudia M Espitia, Weiguo Zhao, et al.
Journal of Cellular and Molecular Medicine
|
November 25, 2010
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
Kevin R Kelly, Jeffrey Ecsedy, Ernest Medina, et al.
Oncotarget
|
October 30, 2015
Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus
Kevin R Kelly, Claudia M Espitia, Weiguo Zhao, et al.
The Journal of Biological Chemistry
|
December 15, 2010
Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis
Jennifer S Carew, Claudia M Espitia, Juan A Esquivel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 13, 2014
The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine
Steffan T Nawrocki, Kevin R Kelly, Peter G Smith, et al.
Haematologica
|
September 2, 2017
CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
Yasuhiro Oki, Kevin R Kelly, Ian Flinn, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 21, 2018
A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma
Sikander Ailawadhi, Kevin R Kelly, Robert A Vescio, et al.
British Journal of Haematology
|
August 21, 2014
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events
Swaminathan P Iyer, Joseph Taddeus Beck, A Keith Stewart, et al.
International Journal of Cancer
|
April 11, 2012
Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism
Kevin R Kelly, Steffan T Nawrocki, Claudia M Espitia, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 48) with videos related to
Sort By:
Page
of 5
Current Drug Targets
|
July 23, 2011
Targeting aurora kinases in cancer treatment
Kevin R Kelly, Jeffrey Ecsedy, Devalingam Mahalingam, et al.
Blood Advances
|
April 25, 2019
Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity
Jennifer S Carew, Claudia M Espitia, Weiguo Zhao, et al.
Journal of Cellular and Molecular Medicine
|
November 25, 2010
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
Kevin R Kelly, Jeffrey Ecsedy, Ernest Medina, et al.
Oncotarget
|
October 30, 2015
Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus
Kevin R Kelly, Claudia M Espitia, Weiguo Zhao, et al.
The Journal of Biological Chemistry
|
December 15, 2010
Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis
Jennifer S Carew, Claudia M Espitia, Juan A Esquivel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 13, 2014
The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine
Steffan T Nawrocki, Kevin R Kelly, Peter G Smith, et al.
Haematologica
|
September 2, 2017
CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
Yasuhiro Oki, Kevin R Kelly, Ian Flinn, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 21, 2018
A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma
Sikander Ailawadhi, Kevin R Kelly, Robert A Vescio, et al.
British Journal of Haematology
|
August 21, 2014
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events
Swaminathan P Iyer, Joseph Taddeus Beck, A Keith Stewart, et al.
International Journal of Cancer
|
April 11, 2012
Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism
Kevin R Kelly, Steffan T Nawrocki, Claudia M Espitia, et al.
Page
of 5